Preclinical analyses established [177Lu]Lu-rhPSMA-7.3 as a potential alternative to [177Lu]Lu-PSMA-I&T which has similar clearance kinetics and a similar radiation dose to healthy organs but superior tumor uptake and retention (Yusufi et al. 2021). The gene discussed is FOLH1; the disease is neoplasm.